Biocompatibles turns to new target for PC (phosphorylcholine) technology
This article was originally published in Clinica
Executive Summary
UK company Biocompatibles has announced the first element of its strategic review of its business following the sale of its coronary stent business to Abbott earlier this year. The company plans to use its phosphorylcholine (PC) coating for PC Gel Systems - or polyionic complexes - a gel matrix containing PC. The programme, which has a range of applications including drug delivery, combines the company's expertise in polymer systems and drug-eluting devices, Biocompatibles says.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.